Ioana Hinshaw, MD
Hematology & Oncology · Denver, CONPI 1033193180
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,755 of the $22,266 with a category attached, or 75.2%. It is spread thinly across 21 manufacturers, the largest accounting for just 21.1%. 2025 is the largest year on record at $7,626, 7.7 times the $995 reported in 2019.
Across 37 payments — averaging $601.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$5K
- Beigene USA, Inc.$2K
- EMD Serono, Inc.$2K
- Springworks Therapeutics, Inc.$2K
- Athenex Pharmaceutical Division, LLC$2K
- AstraZeneca$1K
- plus $8K from 15 others
What the payments were for
- Consulting fees$16,75575%
- Speaking & faculty fees$3,85017%
- Food & beverage$9234%
- Education$620%
- Gifts$6773%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 2 | $4,700 |
| Beigene USA, Inc. | 3 | $2,380 |
| EMD Serono, Inc. | 1 | $2,115 |
| Springworks Therapeutics, Inc. | 4 | $2,045 |
| Athenex Pharmaceutical Division, LLC | 3 | $1,750 |
| AstraZeneca | 1 | $1,375 |
| Eisai Inc. | 1 | $1,365 |
| Seagen Inc. | 1 | $1,230 |
| Deciphera Pharmaceuticals Inc. | 1 | $1,100 |
| Aadi Bioscience, Inc. | 1 | $1,000 |
| Genentech USA, Inc. | 1 | $910 |
| Incyte Corporation | 1 | $860 |
| Tosoh Bioscience, Inc. | 1 | $677 |
| Novartis | 3 | $231 |
| Hologic Sales And Service, LLC | 1 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $119 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $100 |
| Pfizer | 3 | $75 |
| Gilead(2 entities) | 3 | $47 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Epizyme, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BLENREP$2,750
- OGSIVEO$2,000
- ZEJULA$1,950
- Oral Paclitaxel$1,750
- Encequidar$1,750
- IMFINZI$1,375
- LENVIMA$1,365
- FER, ST AIA-PACK$1,354
- TUKYSA$1,230
- VIMSELTINIB$1,100
- FYARRO$1,000
- Herceptin$910
- Perjeta$910
- Kadcyla$910
- ZYNYZ$860
- ACESSA PROVU SYSTEM$127
- KISQALI$125
- PIQRAY$125
How this compares
$22,266 in reported general payments places this provider in the 75th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TukysaTucatinib | 13 | $318,199 |
| RevlimidLenalidomide | 15 | $306,312 |
| CalquenceAcalabrutinib Maleate | 16 | $241,338 |
| ImbruvicaIbrutinib | 12 | $210,718 |
| JakafiRuxolitinib Phosphate | 11 | $109,782 |
| EliquisApixaban | 71 | $61,628 |
| XareltoRivaroxaban | 34 | $41,547 |
| OxycontinOxycodone Hcl | 11 | $14,696 |
| Anastrozole | 228 | $4,616 |
| Enoxaparin Sodium | 36 | $3,355 |
| Letrozole | 66 | $1,304 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 14 | $1,186 |
| Imatinib Mesylate | 11 | $824 |
| Hydroxyurea | 22 | $670 |
| Tamoxifen Citrate | 24 | $651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Seagen Inc.Tukysa | $1,230 | $318,19913 claims |
| AstraZenecaCalquence | $1,375 | $241,33816 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $100 | $210,71812 claims |
| Incyte CorporationJakafi | $860 | $109,78211 claims |
| PfizerEliquis | $75 | $61,62871 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Denver
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- Robert RifkinDenver$270K
- Mabel MardonesDenver$149K
- Peter ForsbergDenver$147K
- Peter McSweeneyDenver$126K
- Alireza EghtedarDenver$96K
- Jeffrey MatousDenver$93K
- Tara GregoryDenver$67K
- Michael TeesDenver$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.